Trading frenzy in the neuroscience field is repeated, and top venture capitalists join forces with Amgen to establish a new company for US$500 million

There is no doubt that the decade beginning in 2020 will be a decade of rapid development in neuroscience

In 2020, a large amount of investment has poured into the field of neuroscience, which is the highest amount of investment in the past ten years, with a total of more than 2.

In this investment tide, several neuroscience start-up companies have received high A round of financing

Source: DealForma.

ARCH Venture Partners is a venture capital company that is very optimistic about neuroscience drug research

On October 7th, the venture capitalist who specializes in creating biotech companies on its own announced that it will inject 500 million US dollars to establish Neumora, of which 400 million US dollars will come from various leading venture capital companies, and 100 million US dollars will come from Amgen’s equity investment.

Kristina Burow, executive director of ARCH and co-founder of Neumora, said: "For a long time, people have always believed that research in the field of neurodegeneration and neurobehavior is too difficult, but we completely reject this view

If Neumora can succeed, it is because the latest advances in genomics and neurobiology have laid the foundation for more targeted regulation of the underlying biology of specific brain diseases, just as the field of oncology has shifted from targeting organs to focusing on Molecularly defined diseases are the same

Neumora finally came into being from the acquisition of three start-up companies that also belong to ARCH, as well as the assets of two other companies

Neumora has annexed BlackThorn Therapeutics, a neuroscience company recently incorporated into ARCH, which has just raised $76 million in Series B financing

In order to contribute to its own pipeline, Neumora also reached a research and development cooperation agreement with Amgen

Thus, Neumora has a total of 8 drug molecules under investigation, of which two are in the clinical stage

Reference source:

1.